[go: up one dir, main page]

WO1992008474A3 - Treatment of lung diseases - Google Patents

Treatment of lung diseases Download PDF

Info

Publication number
WO1992008474A3
WO1992008474A3 PCT/GB1991/002049 GB9102049W WO9208474A3 WO 1992008474 A3 WO1992008474 A3 WO 1992008474A3 GB 9102049 W GB9102049 W GB 9102049W WO 9208474 A3 WO9208474 A3 WO 9208474A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
provides
cyclosporin
corticosteroids
identified
Prior art date
Application number
PCT/GB1991/002049
Other languages
French (fr)
Other versions
WO1992008474A2 (en
Inventor
Anthony Barry Kay
Neil Christopher Barnes
Peter John Cole
Original Assignee
Nat Heart & Lung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909025154A external-priority patent/GB9025154D0/en
Application filed by Nat Heart & Lung Inst filed Critical Nat Heart & Lung Inst
Publication of WO1992008474A2 publication Critical patent/WO1992008474A2/en
Publication of WO1992008474A3 publication Critical patent/WO1992008474A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Specific pharmacological targeting of T-lymphocytes provides a new approach to the treatment of chronic asthma (both in patients relatively sensitive and resistant to the effects of corticosteroids) and to the treatment of other lung deseases such as bronchiectasis and cystic fibrosis, as well as sinusitis. The invention provides the use of cyclosporin A and other immunosuppressive agents with the same or similar mode or site of action for the treatment of diseases characterised by airflow obstruction and/or of chronic sinusitis. Suitable other agents include FK 506, rapamycin and humanised anti-CD4 antibodies. The invention also provides an in vitro test for prediction of clinical response to corticosteroids and immunosuppressive agents. Corticosteroid resistance can be identified by the in vitro test and corticosteroid-resistant patients thus identified can be treated by cyclosporin A or other suitable immunosuppressive agent.
PCT/GB1991/002049 1990-11-20 1991-11-20 Treatment of lung diseases WO1992008474A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909025154A GB9025154D0 (en) 1990-11-20 1990-11-20 Treatment of lung diseases
GB9025154.7 1990-11-20
GB9026620.6 1990-12-07
GB909026620A GB9026620D0 (en) 1990-11-20 1990-12-07 Treatment of lung diseases

Publications (2)

Publication Number Publication Date
WO1992008474A2 WO1992008474A2 (en) 1992-05-29
WO1992008474A3 true WO1992008474A3 (en) 1992-06-25

Family

ID=26297977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002049 WO1992008474A2 (en) 1990-11-20 1991-11-20 Treatment of lung diseases

Country Status (2)

Country Link
AU (1) AU8910891A (en)
WO (1) WO1992008474A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994008619A1 (en) * 1992-10-08 1994-04-28 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
MX9603773A (en) * 1994-03-03 1997-07-31 Genentech Inc Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders.
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997010806A1 (en) * 1995-09-19 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Aerosol compositions
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
EP1100495A4 (en) * 1998-07-28 2002-09-25 Smithkline Beecham Corp Propenamides as ccr5 modulators
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
AU756677B2 (en) * 1999-03-02 2003-01-23 Centocor Inc. Anti-TNFalpha antibodies in therapy of asthma
US20060083754A1 (en) * 2003-02-10 2006-04-20 Anthony Winiski Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
US20050089517A1 (en) * 2003-09-23 2005-04-28 Shames Richard S. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
JP2007516951A (en) * 2003-12-30 2007-06-28 アステラス製薬株式会社 Use of macrolides for the treatment or prevention of airway obstruction
US20100087474A1 (en) * 2005-04-27 2010-04-08 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
SI2215119T1 (en) 2007-11-13 2013-04-30 Evec Inc. Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, file 155, Medline, 66- 92, Dialog Accession No. 06229897, Lagrue G. et al.: "Membranoproliferative glomerulonephritis assosiciated with Buckley's syndrome treated with cyclosporin. Glomerulonephrite membrano-proliferative associee a un syndrome de Buckley traitee par la ciclosporine", & Presse Med Apr 11 1987, 16 (13) p619-21 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07458632, Fukuda T.: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin A", & Arerugi May 1990, & Arerugi May 1990, 39 (5) p483-7 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07590095, Fukuda T. et al: "The role of eosinophils, neutrophils and lymphocytes for the development of bronchial hyperresponsiveness in a guinea pig model of asthma", & Nippon Kyobu Shikkan Gakkai Zasshi Oct 1990, 28 (10)p128 8-93 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07858952, Szczeklik A. et al: "Cyclosporin for steroid-dependentasth ma", & Allergy May 1991, 46 (4) p312-5 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07902257, Fukuda T. et al: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506", & Int Arch Allergy Appl Immunol (SWITZERLAND) 1991, 94 (1-4) p259-61 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 4856115, Pedersen C. et al.: "Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells", & Allergy (COPENH) 40 (2), 1985, 103-107 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 7905334, Finnerty N.A. et al.: "Effect of cyclosporine on corticosteroid dependent asthma", & J Allergy Clin Immunol 87 (1 part 2), 1991, 297 *

Also Published As

Publication number Publication date
AU8910891A (en) 1992-06-11
WO1992008474A2 (en) 1992-05-29

Similar Documents

Publication Publication Date Title
WO1992008474A3 (en) Treatment of lung diseases
Epstein et al. Time course of hemosiderin production by alveolar macrophages in a murine model
Wardlaw et al. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
US5837713A (en) Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
Ip et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
JP3434824B2 (en) Immunosuppressants and antiallergic compounds such as N- (3-oxyhexanoyl) homoserine lactone
Fujisawa et al. The neutrophil and chronic allergic inflammation
WO1999020261A3 (en) Use of antigunal agents for the topial treatment of fungus-induced mucositis
ITMI912296A0 (en) NEW PREGNA 1,4-DIENE-3,20.DIONE-16,17-ACETAL-21-ESTERS, PROCEDURE FOR THEIR PREPARATION, COMPOSITION AND METHODS FOR THE TREATMENT OF INFLAMMATORY STATES
Paolieri et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines
WO2005099776A3 (en) Steroid sparing agents and methods of using same
US5318958A (en) Amyloid precursor protein
RU2004123463A (en) Steroid sapogenins and their derivatives for the treatment of diseases
CY2009010I1 (en) METHOD FOR ENRICHMENT OF R-EPIMER OF 16,17-ACETAL DERIVATIVES OF 21-ACYLOXY PREGNA-1,4-DIEN-11.BETA., 16.ALPHA., 17.ALPHA.-TRIOL-3,20-DIONE
BR9811823A (en) Method and compositions for treating late-stage allergic reactions and inflammatory diseases
Patella et al. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
MX9603596A (en) Prevention and treatment of topical viral infections with perfluoropolyether compounds and compositions including perfluoropolyether compounds.
Moqbel et al. The effect of platelet-activating factor on IgE binding to, and IgE-dependent biological properties of, human eosinophils
Dalakas The role of high-dose immune globulin intravenous in the treatment of dermatomyositis
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2001082953A3 (en) Methods for treatment of diseases associated with inflammation under non-ischemic conditions
Mehindate et al. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone.
Skowron et al. Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′, 3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
Aoki et al. Protective effects of a novel nonglucocorticoid 21-aminosteroid (U74006F) during traumatic shock in rats
WO2003103723A3 (en) Neutrophil imaging methods in cyctic fibrosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA